Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abionic's New POC Sepsis Test On Rapid Move To Market

Executive Summary

Swiss start-up Abionic has CE marked rapid tests for sepsis and iron deficiency, designed to run on its diagnostics platform abioSCOPE. The new sepsis test is based on a new biomarker PSP which has shown to be superior to current tests in detecting this life threatening condition early.

You may also be interested in...



Abionic Scores $21m To Push Through 5-Min Sepsis Test

Swiss diagnostics developer Abionic has scored CHF20m ($21m) in Series C financing from a syndicate of high-net-worth individuals to kickstart a multinational study into the efficacy of its Pancreatic Stone Protein (PSP) test for rapid sepsis risk assessment and management.

OUS Approvals Analysis: Medtronic, Abbott, Abionic Lead 2017 Upswing

The 20 non-US medical device approvals in January, including eight in in vitro diagnostics, four in orthopedics, and three in cardiovascular devices. Big medtech players Medtronic and Abbott, accompanied by much smaller Swiss IVD firm Abionic, led the charge and bagged more OUS approvals than most.

Sequana Medical Secures $21M In Private Placement

One year on from its IPO on Euronext Brussels, abdominal implant maker Sequana Medical has secured €19m ($21m) in an equity placement. The company said it had been backed by new and existing investors. 

Topics

Related Companies

UsernamePublicRestriction

Register

MT104340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel